Brand Name
Intelence
Generic Name
Etravirine
View Brand Information FDA approval date: January 18, 2008
Classification: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Form: Tablet
What is Intelence (Etravirine)?
INTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see Microbiology (1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment